Contraindications: PropiTrex must not be used by individuals with known or suspected androgen-sensitive carcinoma of the prostate or male breast, existing polycythaemia, untreated severe cardiac insufficiency, or hypersensitivity to Testosterone Propionate or any component of the formulation. Women who are pregnant or may become pregnant must avoid all testosterone injectables.
Side Effects: Androgenic effects including acne, accelerated scalp hair recession, and increased sebum production are common dose-dependent responses. Aromatisation of testosterone to oestradiol can produce gynaecomastia and water retention; an aromatase inhibitor should be available before beginning any cycle. Injection-site pain and transient nodule formation are more frequent with short-ester propionate preparations than with longer-ester counterparts. Polycythaemia (elevated haematocrit) requires monitoring and possible dose adjustment.
Monitoring: Obtain a full blood panel — including serum testosterone, oestradiol (E2), LH, FSH, haematocrit, haemoglobin, and hepatic enzyme markers — at baseline, at week 4, and at cycle end. Haematocrit exceeding 54% warrants dose reduction or temporary cessation. Blood pressure should be self-monitored weekly, particularly during higher-dose advanced protocols.
PCT: Because Testosterone Propionate clears from circulation relatively quickly after the final injection (detectable androgen suppression resolves faster than with long-ester testosterones), post-cycle therapy with a SERM such as Nolvadex or Clomid can typically commence within 3–5 days of the last PropiTrex injection. Standard PCT duration is 4 weeks; bloodwork at PCT conclusion confirms hypothalamic–pituitary–gonadal axis recovery.